News

Photo

German Merck Licenses Fusion Protein to PDS

Germany‘s Merck has granted an exclusive license for the tumor-targeting IL-12 fusion protein currently known as M9241 to PDS Biotechnology Corporation, a US-based clinical-stage immunotherapy company with a growing pipeline of targeted immunotherapies for cancer and infectious disease.

Photo

KBR Wins Indian VAM Project

US-based multinational contractor KBR and its Japanese acetyls technology partner Showa Denko have been selected by Asian Paints to provide services for a grassroots vinyl acetate monomer (VAM) plant in India.

Photo

CEFIC Concerned by Revision of EU CLP Regulation

On December 19, 2022, the European Commission proposed a revised regulation on Classification, Labelling and Packaging (CLP) of chemicals and introduced new hazard classes for endocrine disruptors, as well as for chemicals that do not break down in the environment and can accumulate in living organisms, or risk entering and spreading across the water cycle, including drinking water.

Photo

Moderna Buys Japan’s OriCiro Genomics

In its first acquisition since forming in 2010, mRNA specialist Moderna is buying Japan’s OriCiro Genomics for $85 million, expanding its therapeutics and vaccines portfolio.

Photo

Arkema Completes Divestment of Febex

Arkema has finalized the divestment of Febex, a company specialized in phosphorus-based chemistry, as a further step in what it calls its ”dynamic portfolio management strategy.” Buyer is Belgian group Prayon; the acquisition price was not disclosed.

Photo

ADNOC to Take a 24.9% Stake in OMV

In a deal announced shortly before Christmas that only attracted significant attention in the new year, Abu Dhabi National Oil Company (ADNOC) said it is acquiring a 24.9% stake in Austrian energy group OMV from Mubadala, the sovereign wealth fund of the United Arab Emirates.

Photo

Nouryon Closes ADOB Acquisition

Nouryon announced on Jan. 4 that it had closed its purchase of ADOB, a Poland-based supplier of chelated micronutrients, foliars and other specialty agricultural solutions.

Photo

Novartis to Pay $245 Million in ’Pay for Delay’ Settlement

Novartis has agreed to pay a total of $245 million to settle lawsuits filed by direct purchasers, indirect purchasers and retailers accusing it of colluding with Par Pharmaceutical to delay the launch of a generic version of its Exforge (valsartan/amlodipine) hypertension drug.

Photo

Biden EPA Revives Waters of the United States

Just before the New Year, the administration of US president Joe Biden revived Waters of the United States, a section of former president Barack Obama’s Clean Air Act that had been deleted by Donald Trump in a move rejected by a federal court.

Photo

ExxonMobil Starts up Advanced Recycling Plant

ExxonMobil has started up what it says is one of the largest advanced recycling facilities in North America at its integrated manufacturing complex in Baytown, Texas, where the company uses proprietary Exxtend technology to break down hard-to-recycle plastics and process them into chemical feedstock.

Photo

3M Announces Exit from PFAAS

US consumer products giant 3M has announced it will discontinue production and use of perfluoroalkyl and polyfluoroalkyl substances, (PFAS) across its products by the end of 2025.

Photo

Arkema Doubles Polyester Resin Output in India

Arkema has doubled capacity for its Reafree-branded powder polyester resins at its Navi Mumbai facility in India. The French chemical producer said the upgrade reinforces its leadership position in the global powder coatings market and its commitment to developing very low-VOC technologies.

Photo

New German Hydrogen Pipeline Network in Planning

German utility companies Gascade, Ontras and Terranets BW are planning to create a 1,100 km pipeline system with up to 20 GW capacity to transport renewable hydrogen across the country from north to south.

Photo

Topsoe Wins Ammonia, Methanol Contracts

Danish technology company Haldor Topsoe has been chosen by Ascension Clean Energy (ACE) to provide its Syncor autothermal reforming technology for a world-scale ammonia plant to be built in Louisiana, USA.

Photo

Jobs to Go at Novartis US Headquarters

As part of plans, announced in dribbles, to carve 8,000 jobs out of its global workforce to save $1 billion, Swiss drugs giant Novartis is eliminating 285 staff positions across its headquarters sites in the US state of New Jersey.

Photo

Trinseo Closes German Styrene and PC Production

Trinseo has finally decided to stop producing styrene at its Böhlen site in Germany, saying the plant – producing about 300,000 t/y – is too small to be competitive on the global market with current high gas prices and new styrene capacity additions sealing the unit’s fate.

Photo

Brenntag Expands South American Facilities

Brenntag has opened a new facility in Zarate, Argentina, unifying its operations in Buenos Aires into a single site and expanding its capabilities to customers. The site comprises offices, warehouses, storage tanks, three tank truck unloading spaces, two drumming stations and a mixing and blending building.

Photo

BioNTech to Set up Oncology Base in Taiwan

Germany’s BioNTech said it plans to accelerate and broaden the clinical development of its cancer immunotherapy pipeline in the Asia-Pacific region by expanding its clinical footprint to East Asia, specifically Taiwan.

Photo

German Chemicals Stagger under Energy Burden

The global chemical industry has seen its share of challenges, but the sector has traditionally mustered its considerable resources to manage them with a minimum of casualties. Crisis here, recession there, when all blows over, it‘s “business as usual.”

Photo

GSK and Wave Life Sciences Partner on Genetics

British pharma GSK has entered into a four-year collaboration with US clinical-stage genetic medicines company Wave Life Sciences to advance oligonucleotide therapeutics, including Wave’s preclinical RNA-editing program targeting alpha-1 antitrypsin deficiency (AATD), an inherited disorder that can cause lung and liver disease.

Photo

Synthomer Sells Laminates, Films and Fabrics to Surteco

UK chemicals company Synthomer is selling its laminates, films and coated fabrics businesses to Germany’s Surteco Group for $255 million. The sale is part of Synthomer’s realignment of its portfolio to focus on specialty chemicals.

Photo

Chinese Distributor Inks Paxlovid Deal with Pfizer

As Covid cases continue to explode across the country, China Meheco Group Co, an internationally active manufacturer and distributor of pharmaceuticals chemicals and biologicals as well as Chinese traditional medical products, has struck a deal with Pfizer to distribute the US pharma giant’s oral antiviral Paxlovid in the People’s Republic.

Photo

Clariant Expands Care Chemicals in China

Specialty chemicals producer Clariant said it will invest 80 million Swiss francs to increase output of existing products in the portfolio it manufactures at Daya Bay, Huizhou, China, as well as introducing new products there by the end of 2024.

Photo

Takeda Takes Nimbus Lakshmi for $4 Billion

Japanese pharma Takeda is acquiring Nimbus Lakshmi, a wholly-owned subsidiary of US clinical-stage drug discovery company Nimbus Therapeutics, and its tyrosine kinase 2 (TYK2) inhibitor NDI-034858, which is undergoing trials for treating multiple autoimmune diseases, including psoriasis.

Photo

Pfizer to Invest $750 million in Michigan

Pfizer is planning to invest $750 million in its Kalamazoo County, Michigan, production site – one of its biggest – to increase output of injectables and vaccines, including the investigational mRNA flu shot currently in Phase 3 clinical trials.

Photo

Amgen Boosts Rare Diseases with Horizon Buy

Amgen has agreed to buy Horizon Therapeutics for $28.3 billion including debt, boosting its portfolio of drugs for rare autoimmune and inflammatory diseases and beating rivals Sanofi and Johnson & Johnson, as well as a fourth unnamed company.

12398 more News

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.